Mutants of a lovastatin-hyperproducingAspergillus terreus deficient in the production of sulochrin

Victor A. Vinci, T. D. Hoerner, Allen D. Coffman, Timothy G. Schimmel, Rebecca Dabora, A. C. Kirpekar, Carolyn L. Ruby, R. W. Stieber

Journal of Industrial Microbiology & Biotechnology · 1991 · 61 citations · 14 references

Concepts

Abstract

A lovastatin-hyperproducing culture ofAspergillus terreus was shown to produce several co-metabolites extracted from whole broth. The predominant co-metabolite was the benzophenone, sulochrin, reported to arise from a polyketide biosynthetic pathway. This compound was targeted for elimination by classical mutagenesis and screening. A surface culture method employing microtiter, plates was used to ferment mutants for the primary screen. Qualitative determinations of lovastatin and sulochrin production were achieved by high-performance thin-layer chromatography. A mutant, strain AH6, which produced lovastatin titers equivalent to the parent culture and no detectable sulochrin was isolated. In addition, a lovastatin-hyperproducing mutant designated CB4 was capable of producing 16% more lovastatin and 30% less sulochrin than the parent culture in shake flask fermentations. In a pilot-scale 250-gallon fermentation, strain CB4 gave a 20% increase in lovastatin titer while producing 83% less sulochrin than the parent culture.

References

14